News articles about Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Inotek Pharmaceuticals Corporation earned a daily sentiment score of 0.06 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.5511279700951 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Inotek Pharmaceuticals Corporation (ITEK) – Traders Alert on Unusual Volume Activity – Wall Street Morning (wallstreetmorning.com)
- Inotek Pharmaceuticals Announces Filing of Preliminary Proxy Statement for Proposed Merger with Clinical-stage … – Business Wire (press release) (businesswire.com)
- Pre-Market Most Active for Oct 13, 2017 : BAC, MON, ITEK, WFC, GSK, GE, T, MSFT, AAPL, CSCO, INTC, CMCSA – Nasdaq (nasdaq.com)
- Inotek Pharma Cmn (ITEK) A Look at Technical Overview – ExpertGazette (expertgazette.com)
- Wall Street’s M&A Chatter From October 12: Kroger, Genesis Capital, Inotek Pharma-Rocket Pharma – Benzinga (benzinga.com)
ITEK has been the topic of several research analyst reports. Canaccord Genuity set a $3.00 price target on shares of Inotek Pharmaceuticals Corporation and gave the stock a “buy” rating in a research note on Monday, June 26th. HC Wainwright lowered shares of Inotek Pharmaceuticals Corporation from a “buy” rating to a “neutral” rating and set a $2.00 price target on the stock. in a research note on Tuesday, July 11th. Finally, Zacks Investment Research upgraded shares of Inotek Pharmaceuticals Corporation from a “hold” rating to a “buy” rating and set a $1.00 price target on the stock in a research note on Friday, July 14th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Inotek Pharmaceuticals Corporation presently has an average rating of “Hold” and an average target price of $3.80.
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) opened at 2.74 on Friday. The firm has a 50-day moving average of $1.64 and a 200-day moving average of $1.59. Inotek Pharmaceuticals Corporation has a 1-year low of $0.85 and a 1-year high of $8.05. The firm’s market capitalization is $74.01 million.
Inotek Pharmaceuticals Corporation (NASDAQ:ITEK) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.23. On average, analysts expect that Inotek Pharmaceuticals Corporation will post ($1.05) earnings per share for the current year.
Inotek Pharmaceuticals Corporation Company Profile
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.
Receive News & Ratings for Inotek Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotek Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.